Bone loss is one of the major complications of advanced cancers such as breast cancer, prostate cancer and multiple myeloma; agents that can suppress this bone loss have therapeutic potential.
Introduction
Bone metastasis is a common complication of advanced cancers such as breast cancer and prostate cancer. Depending on the site of primary tumor, metastasis to bone occurs in as many as 70% of patients with metastatic disease and often results in skeletal morbidity (1, 2) . Sequelae of bone metastasis include hypercalcemia of malignancy, severe bone pain and debilitating skeletal morbidity (1, 2) . Bone metastases are commonly characterized as osteolytic, osteoblastic/osteosclerotic or mixed. While breast cancer is most often associated with osteolytic or mixed metastases, osteoblastic metastases are common in prostate cancer. Osteolytic lesions are due to a marked increase in osteoclast number with reduced osteoblastic activity. Parathyroid hormone-related protein (PTHrP) is known as a major player between tumor and bone cells and induces the osteolytic process in part through activation of the RANKL pathway (3) . In contrast to osteolytic lesions, osteosclerotic metastases are defined by a dramatic increase in new bone formation, but they always possess a resorption component (4, 5) .
Breast cancer cells produce factors that induce osteoclastogenesis, PTHrP and interleukins (IL)-1, -6 and -11, which act on bone-forming osteoblasts to increase production of an essential osteoclast stimulator, receptor activator of nuclear factor-kappaB (RANK) ligand (RANKL) (4, 6, 7) . RANKL-induced osteoclastogenesis is mediated through the cell surface receptor RANK. The interaction of RANKL with RANK leads to recruitment of tumor necrosis factor (TNF) receptor-associated factor to cell surface receptor RANK and then activate NF-κB signaling pathways (8) . Indeed, secretion of RANKL by various tumor cells induces osteoclastogenesis (9) (10) (11) (12) . Therefore, selective modulation of RANKL signaling pathways may Identification of novel targets for traditional medicine provides a reverse pharmacology or "bedside to bench" approach for novel drug discovery. We report here our investigation of the potential of plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone; Figure 1A) , derived from the root of an Ayurvedic plant, Plumbago zeylanica L. (also known as Chitrak), to modulate RANK signaling and bone loss. This compound has also been identified in Juglans regia (English walnut), Juglans cinerea (butternut and white walnut) and Juglans nigra (black walnut) (13) .
Plumbagin has been shown to exert antibacterial (14) , antifungal (15) , anti-atherosclerotic (16) and anticancer effects (17) (18) (19) through a variety of mechanisms, including induction of ROS (20); suppression of NF-κB (13), AKT/mTOR (21) and STAT3 (22) ; induction of p53 and JNK (23); activation of the NRF2-ARE pathway (24) and direct inhibition of histone acetyltransferase p300 (25) . In animal studies it has been shown to be chemopreventive for colon cancer (26) and to exhibit antitumor activity in prostate cancer (27) .
We investigated whether plumbagin can suppress the RANKL-induced NF-κB activation pathway and osteoclastogenesis. Whether this vitamin K analogue can affect osteoclast differentiation induced by tumor cells was also examined. Moreover, we investigated whether Electrophoretic mobility shift assays for NF-κB -Nuclear extracts were prepared as described previously (29) .
Western blot analysis -To determine the levels of protein expression in the cytoplasm or nucleus, we prepared extracts (30) and fractionated them by 10% sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE). After electrophoresis, the proteins were electrotransferred to nitrocellulose membranes, blotted with each antibody, and detected by enhanced chemiluminescence reagent (GE Healthcare).
IKK assay -To determine the effect of plumbagin on RANKL-induced IKK activation, IKK assay was done by a method described previously (30) . 
Results
The aim of this study was to investigate the effect of vitamin K3 analogue plumbagin on osteoclastogenesis induced by RANKL or by tumor cells and on cancer-induced bone loss in animals. We used the RAW 264.7 cell (murine macrophage) system, as it is a well-established model for osteoclastogenesis (32) . Whether plumbagin could modulate osteoclastogenesis induced by tumor cells such as breast cancer and multiple myeloma was another focus of these studies. We also investigated the effects of plumbagin on cancer cell−mediated bone loss in athymic nude mice bearing human breast cancer.
Plumbagin represses RANKL-induced NF-κB activation in RAW 264.7 cells. Binding of RANKL to its receptor RANK activates TNF receptor−associated factor 6, which is linked to activation of NF-κB. We investigated whether plumbagin modulates RANKL-induced NF-κB activation in monocytic RAW 264.7 cells. Cells were either pretreated with plumbagin for 4 hours or left untreated, then exposed to RANKL at indicated concentrations; nuclear extracts were prepared and NF-κB activation determined by electrophoretic mobility shift assay (EMSA).
As shown in Figure 1B (left panel), RANKL activated NF-κB; however, plumbagin suppressed RANKL-induced NF-κB activation in a dose-dependent manner. We also investigated the duration of incubation required for plumbagin to suppress RANKL-induced NF-κB activation.
Cells were preincubated with 5 μmol/L plumbagin for the indicated time period up to 4 hours and then exposed to RANKL. As shown by EMSA result in Figure 1B To determine the effect of plumbagin on RANKL-induced IκBα degradation, we treated the cells with RANKL for different times in absence and presence of pumbagin; and then examined for NF-κB and IκBα. We found that plumbagin inhibited RANKL induced activation of NF-κB (Fig. 1C) as well as RANKL-induced IκBα degradation (Fig. 1D) . RANKL induced IκBα degradation in control cells as early as 5 minutes after treatment, but in plumbaginpretreated cells RANKL had no effect on IκBα degradation (Fig. 1D ).
Next we investigated the effect of plumbagin on the phosphorylation of IκBα. To determine this, we used the proteasome inhibitor N-acetyl-leu-leu-norleucinal (ALLN) to block RANKL-induced IκBα degradation. Cells were either treated with plumbagin, ALLN or RANKL and then examined for phosphorylation of IκBα. Because of rapid phosphorylation and degradation of IκBα, no band was detected in cells treated with RANKL alone (Fig. 1E) . Thus ALLN was required to see the phosphorylated band. Results clearly indicate that RANKL induces the phosphorylation of IκBα (sixth lane) and that plumbagin pretreatment inhibits the phosphorylation (eighth lane). (Fig.1E) .
Plumbagin suppresses IKK activation induced by RANKL. Degradation of IκB is a tightly
regulated event that is initiated upon specific phosphorylation by activated IKK. We examined the effect of plumbagin on RANKL-induced IKK activation using immune complex assays. The (Fig. 1F, top panel) . To check whether the apparent loss of IKK activity was due to downregulation of IKK protein expression, the levels of the IKK subunits IKKα and IKKβ were tested by western blot analysis. Neither RANKL nor plumbagin affected the expression of IKKα or IKKβ protein (Fig. 1E, middle and bottom panel) . Plumbagin reduces RANKL-induced bone resorption. We also investigated whether the inhibition of RANKL-induced osteoclastogenesis by plumbagin leads to inhibition of bone resorption. RAW264.7 cells were seeded into calcium phosphate apatite−coated plates, treated with plumbagin along with RANKL and incubated for 5 days. After incubation, resorption pit formation was analyzed. RANKL induced pit formation (Fig. 2C, arrows) , whereas plumbagin significantly inhibited RANKL-induced pit formation (Fig. 2C) . These results suggest that Plumbagin acts at an early step of osteoclastogenesis induced by RANKL. To determine at which stage plumbagin inhibits osteoclastogenesis, the vitamin K analogue was added to osteoclast differentiation cultures beginning at day 0, 1 day later, 2 days later, 3 days later or 4 days later. Plumbagin inhibited osteoclastogenesis maximally when added from the beginning with RANKL treatment (Fig. 3A and 3B ). The exposure of precursor cells to plumbagin at later stages (after 3 days) was less effective in preventing osteoclastogenesis (Fig. 3B, fifth column) .
Plumbagin inhibits RANKL-induced osteoclastogenesis.
Since the RAW 264.7 cells exposed to RANKL for 3 days have already committed to osteoclast differentiation, it is reasonable to suggest that plumbagin can block osteoclast differentiation but cannot reverse the differentiation process once cells have committed to the osteoclast.
Plumbagin inhibits osteoclastogenesis induced by tumor cells.
Bone loss is one of the most common complications in patients with breast cancer (33) or multiple myeloma (34) . Whether this vitamin K3 analogue, plumbagin, also blocks tumor cell-induced osteoclastogenesis of RAW 264.7 cells was investigated. As shown in Figure 4 , co-culture of RAW 264.7 cells with human multiple myeloma U266 (Fig. 4A) or MM.1S cells (Fig. 4B ) induced osteoclast differentiation, and plumbagin suppressed this differentiation in a dose-dependent manner. We found, moreover, that human breast cancer cells, such as MDA-MB-231 (Fig. 4C ) and MCF-7 (Fig. 4D) , also induced formation of osteoclasts, and plumbagin suppressed this differentiation (Fig. 4C and 4D ).
These results indicate that osteoclastogenesis induced by tumor cells, is significantly suppressed by plumbagin. 
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Plumbagin suppresses osteolysis in MDA-MB-231 breast cancer tumor-bearing mice. Breast cancer is one of the most common cancers affecting women in western countries, including the United States. In breast cancer patients, the frequency of bone metastasis is much higher than that of lung and liver metastases (1, 4) . To determine whether plumbagin could suppress osteolytic bone metastasis, we injected nude mice with human breast cancer MDA-MB-231 cells, which are triple negative (negative for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2), and treated them with plumbagin (2 mg/kg) or vehicle control for 4 weeks. To identify osteolytic bone metastasis, we analyzed osteolytic lesions by microradiography and micro-CT analysis. As seen in representative radiographs in Figure 5A Due to extensive bone destruction, a decrease in residual trabecular/cancellous bone volume is considered characteristic of tumor-induced osteolytic bone disease. Micro-CT analyses of proximal tibiae (Fig. 6A ) demonstrated that treatment with plumbagin resulted in a significant preservation of cancellous/trabecular bone volume (Fig. 6B) , which was accompanied by a significant increase in trabecular connectivity density in plumbagin-treated tumor-bearing mice compared to the vehicle-treated tumor-bearing mice (Fig. 6C) . Although there was a small increase in trabecular thickness in plumbagin-treated mice, this was not statistically significant (data not shown). 
Discussion
Almost 90% of cancer-associated deaths are due to tumor metastasis. Some of the major organ sites of tumor metastasis include lung, liver, lymph node, brain and bone. Bone metastasis is commonly associated with prostate cancer, multiple myeloma and breast cancer. Breast cancer metastasis to bone leads to osteolytic lesions, and no treatment is available. Because RANKL, a member of the TNF superfamily, has been closely linked with bone loss, it is a novel therapeutic target. In the study presented here, we investigated the effect of plumbagin, an analogue of vitamin K derived from an Ayurvedic plant, for its potential to affect RANKL signaling, osteoclastogenesis and breast cancer−induced osteolytic lesions in mice.
We found that plumbagin exhibits numerous effects: first, it inhibited RANKL-mediated NF-κB activation; second, it inhibited RANKL-induced IκBα phosphorylation and degradation; third, it blocked activation of IKK; fourth, it suppressed RANKL-induced osteclastogenesis; fifth, it abrogated osteoclastogenesis induced by breast cancer and multiple myeloma; and sixth, when given to animals, it suppressed human breast cancer−induced osteolytic lesions in animals. All these observations together suggest the potential of this compound in suppression of cancerassociated bone loss. This is the first report to suggest that plumbagin can abrogate RANKL signaling. The RANKL/RANK interaction results in a cascade of intracellular events, including activation of NF-κB (28, 35) . NF-κB signaling has been shown to play an important role in osteoclastogenesis (36) . NF-κB p50-/-and p52-/-double knockout mice exhibit severe osteopetrosis caused by failure of osteoclast formation (37, 38) . Both p50 and p52 expression are essential for RANKexpressing osteoclast precursors to differentiate into TRAP-positive osteoclasts in response to RANKL and other osteoclastogenic cytokines (39) pathway, plays an essential role in inflammation-induced bone loss and is required for osteoclastogenesis (40) . IKKβ-deficient bone marrow cells do not differentiate to osteoclasts in vitro when stimulated by RANKL. These reports suggest that any drug that can block RANKL signaling would play an important role in suppression of osteoclast formation. In this study, we found that plumbagin indeed suppressed NF-κB activation by RANKL and this suppression correlated with inhibition of osteoclastogenesis.
Breast cancer, prostate cancer and multiple myeloma, all of which metastasize to bone frequently, express proteins that can migrate and anchor in bone, including chemokines (e.g., CXCR4) (41) and proteins that promote pericellular proteolysis and invasion (e.g., matrix metalloproteinases [MMPs]), angiogenesis (42) and osteoclastogenesis (1) . Previous reports from our laboratory and others showed that plumbagin could suppress the expression of MMPs (for invasion) and vascular endothelial growth factor (VEGF; for angiogenesis) in various types of cancer cell lines, including human multiple myeloma (13, 22, 43) . Aziz et al. reported that plumbagin was a potent inhibitor of prostate cancer cell invasion through suppression of cell invasion and metastasis marker protein MMP-9 and VEGF in prostate cancer cell lines and in athymic mice with ectopic implantation of hormone-refractory DU145 cells (27) . These data are in agreement with our report that plumbagin can inhibit metastasis of breast cancer MDA-MB-231 cells to bone, thus leading to decrease of osteolysis in mice.
In the study reported here, we show that plumbagin suppressed the osteoclastogenesis induced by breast cancer and by multiple myeloma cells. Both breast cancer and multiple myeloma are known to produce RANKL (12, 34) and thus exhibit constitutive NF-κB activation (44, 45) . This NF-κB activation can cause induction of osteoclastogenesis via expression of The most widely used agents for prevention of bone loss include synthetic calcitonin, bisphosphonate drugs, raloxifene and teriparatide (synthetic parathyroid hormone). The bisphosphonates, potent inhibitors of osteoclast formation and activity, are the current standard of care and are the most used drugs for treatment of cancer-induced osteolytic diseases. Several reports have indicated, however, that bisphosphonates increase the risk of severe osteonecrosis of the jaw in cancer patients (48) , with devastating consequences for affected patients (49) . It is prudent, therefore, to develop safer antiresorptive strategies to combat lytic and mixed bone lesions in patients with metastatic cancer in the skeleton.
Plumbagin, a naphthoquinone derived from Ayurvedic medicine, has been used routinely in traditional medicine and is quite safe. Numerous reports indicate that it exhibits anticancer activities against a variety of tumors through activation of multiple cell signaling pathways (13, 21, 22, 27, 43, 50) . Compared to bisphosphonates or denosumab, plumbagin is very inexpensive and has minimal side effects. Our data provide the rationale for further animal and human studies with plumbagin for breast cancer−associated bone loss.
Acknowledgement
We thank Kathryn Hale for carefully proof-reading the manuscript and providing valuable comments. We also thank Steve Munoz of the Bone Center at Vanderbilt University Medical 
